Feature | July 09, 2014

Drawing the Line When Evaluating Cost vs. Benefit

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience environment of healthcare reform, there needs to be a clear, quantifiable return of investment (ROI). This is especially true for new medical technologies that are competing with a long-established standard of care, where the new technology must show either a cost-benefit over the older technology, or must show a big improvement in patient outcomes to justify the added expense. With a device that shows only an incremental increase in benefit, say a 1-2 percent or less improvement over existing technology, the question may become one of economics rather than device effectiveness.

This is not only a question for physicians, as it applies to vendors developing these products as well. One of the biggest examples of this is the case of drug-eluting stents. During the last decade, key stent vendors were in an arms race to build a better device and capture a large share of the then lucrative coronary stent market. This included extremely expensive, blockbuster clinical trials, massive R&D efforts, and lawsuits and countersuits to try to slow down the competition. However, this came to a halt with the SPIRIT IV trial results in 2010, which proved the Abbott Xience stent was the best in the market for patient outcomes and beat out the long-time market leader, the Boston Scientific Taxus stent.  

However, the victory only just edged out Taxus. Stent thrombosis improvements were measured in fractions of less than 1 percent, and ischemia-driven target-lesion revascularization improvements were less than a 2.6 percentage-point absolute reduction. The data proving that Abbott was the top performer by only a small margin came at a staggering cost of nearly a billion dollars and several years of data collection. Few vendors are willing to shell out that sort of cash today to conduct similar sized trials that will be powered with enough patients to show only small incremental improvements.  

In reality, all the drug-eluting stents on the U.S. market today are good devices and all have similar patient outcomes. This has led to stents becoming commodity items, where lower pricing can often trump slightly better trial data. This is why the Xience stent does not master the entire stent market and why competitors remain in the game. 

I shared some additional thoughts on things to consider when looking at new devices and software in the article The Basics for Evaluating New Technology in the July-August issue of DAIC.

Related Content

fibrinolysis, FL, STEMI patients, ACCF/AHA guidelines, Minneapolis Heart Institute, AHA Scientific Sessions 2016
News | Cath Lab| November 10, 2016
Current ACCF/AHA guidelines recommend fibrinolysis (FL) as the preferred reperfusion strategy for ST-segment elevation...
 PLATINUM DIVERSITY, stents in minorities and women
News | Cath Lab| November 09, 2016
November 9, 2016 — A dedicated stent study conducted exclusively in women and minority patients evaluated clinical ou
Sponsored Content | Videos | Stents Bioresorbable| November 09, 2016
Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirb
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Sponsored Content | Videos | Cath Lab| November 08, 2016
David Kandzari, M.D., director of interventional cardiology and chief scientific officer, Piedmont Heart Institute, A
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Fortitude bioresorbable stent

The Fortitude sirolimus-eluting bioresorbable stent.

 

News | Stents Bioresorbable| November 07, 2016
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 in Washington, D.C...
Bionics trial, Medinol, BioNIR stent, elastic polymer

Imaging of stent struts after expansion, showing the elastic polymer used on Medinol’s BioNIR stent does not crack or flake off, possibly leading to better patient outcomes. 

News | Stents| November 07, 2016
November 7, 2016 – The large multinational randomized BIONICS study found that a novel elastic polymer coated ridafor
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Overlay Init